Do a good job in upgrading the existing varieties and applying for the development of snake venom serum; Based on the existing products of the company, the upstream and downstream products of the company and the same type of industries are merged, so as to expand the domestic and international markets of the company's biological products, and make the company become an export-oriented biological product enterprise with an emerging position in the international industry.

(1) Complete the production and application of the upgraded product of tetanus antitoxin penicillin bottle, anti Agkistrodon halys venom serum and anti Agkistrodon acutus venom serum.
By the end of 2024, strive to obtain the registration and marketing of the upgraded tetanus antitoxin products;
By the end of 2025, the approval documents for the production of anti Agkistrodon halys venom serum and anti Agkistrodon acutus venom serum,
The product will be put on the market in 2026.
(2) Complete the production and application of anti rabies serum and anti cobra venom serum products. By the end of 2026, we will strive to obtain the production approval of anti rabies serum and anti cobra venom serum products, and the products will be marketed in 2027.
(3) Intervene and explore the research, development, small test, pilot test and production of multivalent snake venom immune serum, and begin to register and apply.

(1) Complete the production and application of multivalent antivenom products. We will strive to obtain clinical approval documents by the end of 2028, product production approval documents by the end of 2030, and the products will be marketed in 2031.
(2) Carry out the research and development of anti COVID-19 serum.
(3) Involved in the selection, research and development, small and medium-sized trials of other new vaccine projects, and began to register and apply.